ED50 of propofol combined with nalbuphine during painless gastroscopy in overweight patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066602

Enrollment

Unknown

Registered

2022-12-11

Start date

2022-12-12

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The painless diagnosis and treatment of overweight patients is safe

Interventions

N1 group:Nalbuphine 0.05mg/kg

N2 group:Nalbuphine 0.1mg/kg

N3 group:Nalbuphine 0.15mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective painless gastroscopy, ASAI-II; 2, aged 18-60 years old 3, BMI between 25-30 kg/m2; 4. No obvious cardiopulmonary disease; 5. Normal communication; 6. Volunteer to take the test and sign the informed consent

Exclusion criteria

Exclusion criteria: (1) patients allergic to anesthetic drugs such as propofol. (2) severe respiratory and circulatory diseases (3) mental disorders such as schizophrenia and depression; (4) complicated with obvious liver and kidney dysfunction; (5) long-term drug abuse: including chemotherapy drugs, analgesics, etc.

Design outcomes

Primary

Measure	Time frame
Median effective dose;Dosage of Propofol;Dosage of Nalbuphine;	—

Secondary

Measure	Time frame
Duration time given initial dose of Propofol;Duration of procedure;Time of opening eyes;Orientation recovery time;incidence of hypoxemia (SpO2 < 95%);Adverse reactions;	—

Countries

China

Contacts

Public ContactChen Lijian

The First Affiliated Hospital of Anhui Medical University

chenlijian@126.com13966699467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026